https://www.live-feeds.com/feed/novartis-stock-tanks-following-third-major-pipeline-setbackContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-stock-tanks-following-third-major-pipeline-setbackhttps://www.live-feeds.com/feed/novartis-stock-tanks-following-third-major-pipeline-setback#u63483Thu, 10 Sep 2026 04:05:32 +0000Novartis shares fell 10% on Thursday, marking a potential record daily loss following a third drug trial failure within seven days. The latest setback involves a Phase 3 study for a neuromuscular RNA drug intended to treat a rare muscle disease. This drug was part of a 12 billion dollar acquisition of Avidity. The series of pipeline disappointments has increased pressure on the pharmaceutical major as it faces multiple high-profile clinical failures in a short window.Why it mattersPipeline setbacks directly impact a pharmaceutical company's future revenue projections and valuation. The fa